Abstract Number: 167 • 2020 Pediatric Rheumatology Symposium
Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
Background/Purpose: Metabolomic and lipidomic pathways serve as key sensors and effectors of genetic, epigenetic, and environmental factors that shape the development and function of the…Abstract Number: 130 • 2019 ACR/ARP Annual Meeting
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Background/Purpose: Traditionally in ELISA detection of APS antibodies, the use of serum is thought to be preferable over plasma according to international consensus bodies. The…Abstract Number: 131 • 2019 ACR/ARP Annual Meeting
Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Background/Purpose: Anti-phosphatidylserine prothrombin antibodies (aPS-PT) are reported to be highly associated with the LAC. Some have suggested a clinically useful role for aPS-PT as a…Abstract Number: 145 • 2019 ACR/ARP Annual Meeting
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results
Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria to identify patients with high likelihood of Antiphospholipid Syndrome…Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…Abstract Number: 4 • 2017 ACR/ARHP Annual Meeting
Downregulation of microRNAs in Plasmacytoid Dendritic Cells Is Associated with a Type I Interferon Signature in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Background/Purpose: The most prominent alteration in the immune system of patients with SLE is a type I interferon (IFN) signature, which we recently also reported…Abstract Number: 1656 • 2017 ACR/ARHP Annual Meeting
Type I Interferon Drives the Dysregulation of Plasmacytoid and Myeloid Dendritic Cells in Systemic Lupus Erythematosus and Antiphospholipid Syndrome
Background/Purpose: Dendritic cells (DC) are the sentinel cells of the immune system that potently activate T-cells, making them important players in the pathophysiology of systemic…Abstract Number: 2095 • 2016 ACR/ARHP Annual Meeting
Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
Background/Purpose: Oxidized low-density lipoprotein (oxLDL), a key molecule in atherogenesis, serves as the source of anionic charged particles that bind to beta2glycoprotein I (Β2GPI) and…Abstract Number: 2992 • 2016 ACR/ARHP Annual Meeting
In Systemic Lupus Erythematosus with Antiphospholipid Antibodies, Hypocomplementemia Associates with Thrombosis
Background/Purpose: Hypocomplementemia is a common phenomenon in systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS). Robust mechanistic data implicate complement activation in antiphospholipid antibody…Abstract Number: 2189 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository (“Registry”) Prospective Follow-up Analysis: One-Year First and Recurrent Thrombosis Risk
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…Abstract Number: 2191 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Acute and Chronic Renal Lesions Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Background/Purpose : Renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their associations with aPL are inconsistent among studies. Therefore our objective…Abstract Number: 2198 • 2015 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Clinical Database and Repository Analysis: Determinants of Thrombosis in Patients Presenting with Obstetric APS
Background/Purpose: APS ACTION Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive…Abstract Number: 2177 • 2015 ACR/ARHP Annual Meeting
Pegylated Recombinant Domain I of Beta-2-Glycoprotein I, a Potential Therapeutic Agent for Antiphospholipid Syndrome, Fully Retains Its Ability to Inhibit Binding of IgG or IgA Antibodies from Patients with APS to Beta-2-Glycoprotein I in Vitro
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical events including vascular thrombosis (VT) and pregnancy morbidity (PM).…Abstract Number: 2652 • 2013 ACR/ARHP Annual Meeting
Ovarian Reserve In Women With Primary Antiphospholipid Syndrome
Background/Purpose: Aging, smoking, obesity and surgery have been found to influence the quantity and quality of primordial follicles in ovaries and, ultimately, the ovarian reserve.…Abstract Number: 2553 • 2013 ACR/ARHP Annual Meeting
The Clinical Value Of Testing For Aphl, a New ELISA Kit With a Unique Phospholipid Mixture In Patients With Systemic Lupus Erythematosus (SLE)
Background/Purpose: Antibodies directed to APhL (a mixture of phospholipids) have been reported to predict APS more reliably than aCL tests. We designed this study to…
ACR Meeting Abstracts